Spread the love

Emyria Limited (Emyria or the Company), a data-backed drug development company, is pleased to announce the expansion of its clinical service subsidiary – Emerald Clinics – with the addition of a second site in Melbourne. The expansion comes off the back of record patient appointments in January 2021.

Emyria’s Managing Director, Dr Michael Winlo, said: “We are pleased to be able to respond to the high patient demand for our clinical care model across Australia with the addition of a new site in Melbourne. The new site is unique in that it is co-located with Victorian Counseling and Psychological Services and offers unique collaboration opportunities with mental health clinicians including psychologists and psychiatrists.

We anticipate that these collaborations will assist our pivotal drug registration clinical trials for EMD-003 – a cannabinoid medicine targeting unmet needs in mental health – as well as support the development of evidence-based clinical protocols and therapy standards for psychedelic-assisted therapy trials. Such trials are currently in development with partner Mind Medicine Australia to help improve our understanding of the role these treatments might play in treating serious mental health concerns like PTSD and major depression.”